

# Morten Hansen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4185627/publications.pdf>

Version: 2024-02-01

46  
papers

1,510  
citations

279798

23  
h-index

330143

37  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2890  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 637420.	2.8	29
2	Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types. <i>Frontiers in Oncology</i> , 2021, 11, 558248.	2.8	17
3	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.7	9
4	Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial. <i>Frontiers in Immunology</i> , 2020, 11, 595035.	4.8	17
5	Development of an In Vitro Assay to Assess Pharmacological Compounds and Reversion of Tumor-Derived Immunosuppression of Dendritic Cells. <i>Immunological Investigations</i> , 2020, 50, 1-17.	2.0	2
6	Tumor miRNA expression profile is related to vestibular schwannoma growth rate. <i>Acta Neurochirurgica</i> , 2020, 162, 1187-1195.	1.7	10
7	Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 2786.	3.7	32
8	Abstract 3091: Liquid biopsy reflecting a T-cell permissive tumor microenvironment identifies metastatic melanoma patients responding to immune checkpoint inhibitor therapy. , 2020, , .		0
9	Long-Term Exposure to Inflammation Induces Differential Cytokine Patterns and Apoptosis in Dendritic Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2702.	4.8	20
10	Inflammation induced PD-L1-specific T cells. <i>Cell Stress</i> , 2019, 3, 319-327.	3.2	13
11	Abstract A079: Secreted IL-12p70 from long-term activated dendritic cells is lost concomitant with their apoptosis and release of IL-10. , 2019, , .		0
12	Assessment of extracellular matrix and tissue derived metabolites in a liquid biopsy for identifying endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14050-e14050.	1.6	0
13	Abstract 2810: Exploring T cell- repertoire in the tumor microenvironment during check-point inhibition in patients with metastatic solid tumors. , 2019, , .		0
14	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1623-1631.	4.4	21
15	Frequent adaptive immune responses against arginase-1. <i>Oncolmmunology</i> , 2018, 7, e1404215.	4.6	27
16	Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. , 2018, 6, 152.		53
17	Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. <i>Cytotherapy</i> , 2017, 19, 500-513.	0.7	58
18	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 918-927.	2.3	72

#	ARTICLE	IF	CITATIONS
19	Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells. <i>Scientific Reports</i> , 2017, 7, 14516.	3.3	77
20	The role of dendritic cells in cancer. <i>Seminars in Immunopathology</i> , 2017, 39, 307-316.	6.1	76
21	Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines. <i>Frontiers in Immunology</i> , 2016, 7, 568.	4.8	59
22	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 955-961.	4.4	50
23	mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. <i>Oncolmmunology</i> , 2016, 5, e1207842.	4.6	29
24	PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncolmmunology</i> , 2016, 5, e1202391.	4.6	33
25	CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1238541.	4.6	56
26	Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21. <i>Cytotherapy</i> , 2016, 18, 1187-1196.	0.7	18
27	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2076-2083.	3.6	24
28	Interferon- $\gamma$ induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 97, 83-92.	2.2	30
29	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 797-804.	4.2	20
30	The effect of short-chain fatty acids on human monocyte-derived dendritic cells. <i>Scientific Reports</i> , 2015, 5, 16148.	3.3	269
31	Selective costimulation by IL-15R/IL-15, but not IL-2R/IL-2, allows the induction of high numbers of tumor-specific CD8+ T cells by human dendritic cells matured in conditions of acute inflammation. , 2015, 3, .		0
32	Expansion of circulating CD56 <sup>bright</sup> natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon- $\gamma$ . <i>European Journal of Haematology</i> , 2015, 94, 227-234.	2.2	45
33	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2790-2795.	3.3	54
34	Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 482.	4.2	43
35	In-chip fabrication of free-form 3D constructs for directed cell migration analysis. <i>Lab on A Chip</i> , 2013, 13, 4800.	6.0	59
36	Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. <i>Vaccine</i> , 2013, 31, 639-646.	3.8	27

#	ARTICLE	IF	CITATIONS
37	Methods to Improve Adoptive T-Cell Therapy for Melanoma: IFN- $\gamma$ Enhances Anticancer Responses of Cell Products for Infusion. <i>Journal of Investigative Dermatology</i> , 2013, 133, 545-552.	0.7	36
38	Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2012, 2, e001803.	1.9	7
39	Characterization of T-cell responses against $\text{H}^2\text{B}^1\text{H}^2$ in cancer patients. <i>Oncolmmunology</i> , 2012, 1, 1290-1296.	4.6	4
40	Cellular Based Cancer Vaccines: Type 1 Polarization of Dendritic Cells. <i>Current Medicinal Chemistry</i> , 2012, 19, 4239-4246.	2.4	28
41	Characterization of Spontaneous Immune Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. <i>Cells</i> , 2012, 1, 51-60.	4.1	2
42	pcaGoPromoter - An R Package for Biological and Regulatory Interpretation of Principal Components in Genome-Wide Gene Expression Data. <i>PLoS ONE</i> , 2012, 7, e32394.	2.5	25
43	IFN- $\gamma$ to improve immunotherapy for melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2565-2565.	1.6	0
44	Cell culture plastics with immobilized interleukin-4 for monocyte differentiation. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 96A, 372-383.	4.0	3
45	Injection molded chips with integrated conducting polymer electrodes for electroporation of cells. <i>Journal of Micromechanics and Microengineering</i> , 2010, 20, 055010.	2.6	36
46	Generating substrate bound functional chemokine gradients in vitro. <i>Biomaterials</i> , 2009, 30, 5305-5311.	11.4	16